Nā ʻIke Hou i nā ʻAno Genetic o ka B-ALL makua

Ianuali 15, 2025, Shanghai – He loiloi hou i paʻi ʻia ma ka puke pai Koko Hāʻawi ʻo ia i kahi loiloi hohonu o nā ʻano genetic o ka makua B-cell Acute Lymphoblastic Leukemia (B-ALL), kahi maʻi ʻino kakaikahi a huhū me ka prognosis maikaʻi ʻole i nā pākeke ke hoʻohālikelike ʻia me nā keiki. I nā makahiki he iwakālua i hala iho nei, ua ʻike ka noiʻi genomic ma mua o 20 mau ʻano genetic like ʻole o B-ALL, kēlā me kēia me nā hopena kūikawā no ka pane lapaʻau a me ka prognosis.

ʻOiai ua hoʻololi nā lāʻau lapaʻau i hoʻololi ʻia i ka pilikia genetic i nā hoʻolālā lapaʻau i ka B-ALL pediatric, ʻaʻole i maopopo loa ke ʻano genetic o ka B-ALL makua. Hōʻike kēia loiloi i nā ʻike koʻikoʻi i ka ʻokoʻa olaola o nā ʻano genetic i nā maʻi makua a hoʻoikaika i ka pono no ka hoʻohui ʻana i ka profiling genetic i nā diagnostics maʻamau e hiki ai i nā hoʻolālā lapaʻau pilikino.

Nā ʻIke Koʻikoʻi:

1. ʻO ke Chromosome Philadelphia-Positive (Ph+) B-ALL:
   ʻO ia ke ʻano maʻamau i nā pākeke, ʻoi aku hoʻi i ka poʻe ma luna o 55, ʻo Ph+ B-ALL ka hopena mai ka gene fusion BCR::ABL1. Ua pili mua me ka prognosis maikaʻi ʻole, ʻo ka hoʻohui ʻana o nā tyrosine kinase inhibitors (TKIs) a me nā monoclonal antibodies i kuhikuhi ʻia, e like me blinatumomab, ua hoʻomaikaʻi nui i nā helu ola. Hōʻike nā hōʻike e kū mai ana i ka heterogeneity biological nui i loko o Ph+ B-ALL, e hōʻike ana i ke koʻikoʻi o nā māka molekala e like me IKZF1 no ka stratification pilikia a me ka hoʻolālā mālama ʻana.

2. Nā Hoʻololi Haʻahaʻa Hypodiploidy a me TP53:
   ʻO ka hypodiploidy haʻahaʻa, i hōʻailona ʻia e ka helu chromosomal o 30-39, ʻoi aku ka nui o ka poʻe mākua a pili pū me nā hopena maikaʻi ʻole. Hōʻike nā haʻawina hou i ke kuleana o nā mutations TP53, i pili pinepine ʻia me ka hematopoiesis clonal, i ka hoʻokele ʻana i kēia subtype kiʻekiʻe-pilikia. Hōʻike nā ʻike ʻaʻole wale kēia mau mutations e hoʻopili i ka hoʻomaka ʻana o ka maʻi akā hiki ke hoʻomaopopo i nā hoʻolālā ma hope o ke kala ʻana.

3. Nā Hoʻonohonoho Hou ʻana o KMT2A:
   ʻIke pinepine ʻia i ka pākeke B-ALL, ua pili nā hoʻonohonoho hou ʻana o KMT2A i nā hopena maikaʻi ʻole. ʻO nā ʻano lapaʻau hou, e like me nā mea hoʻopaʻa menin, he manaʻolana no ka hoʻoponopono ʻana i ke kūʻē lapaʻau kūlohelohe o kēia ʻano.

4. Nā ʻAno Lapaʻau Kakaʻikahi a me nā Lapaʻau Hou:
   ʻO nā ʻano liʻiliʻi e like me TCF3::PBX1 a me TCF3::HLF fusions, ʻoiai he mea kakaikahi, hōʻike i nā ʻano like ʻole o ke olaola a me ke olakino. Hōʻike ka ʻikepili preclinical hoʻoikaika i ka ʻike i nā mea hana hou e like me venetoclax a me nā mea hoʻopaʻa BET, e hoʻomākaukau ana i ke ala no nā koho lapaʻau hou.

Nā hopena lapaʻau:

Ke kāhea nei ka loiloi no ka hoʻokomo maʻamau ʻana o nā ʻano hana profiling genomic holomua, me ka hoʻonohonoho ʻana o ka transcriptome holoʻokoʻa, e ʻike i nā ʻano genetic kikoʻī o ka B-ALL makua. Hiki i kēia ala ke hoʻonui i ka stratification pilikia, alakaʻi i nā hoʻoholo lapaʻau, a hoʻomaikaʻi i ka nānā ʻana i ka maʻi koena liʻiliʻi (MRD).